The applications of BCI in the Treatment of Mental Disorders and the Development of Antipsychotic Drugs

Authors

  • Sai Hong

DOI:

https://doi.org/10.61173/gw8r0r42

Keywords:

BCI, mental disorders, drug development

Abstract

Globally, a wide range of mental disorders continues to significantly impact people’s lives, with traditional treatment methods often falling short of providing effective and systematic solutions. Brain-computer interface (BCI) technology, one of the most rapidly advancing fields, offers promising applications across various sectors of human society, including production, healthcare, and media. By combining different BCI technologies, such as EEG monitoring and Deep Brain Stimulation, medical institutions can now offer patients a broader spectrum of effective or potential treatment options. This paper provides a comprehensive review of the current application status of various representative BCI technologies in mental health treatment. It also explores the prospect of constructing an integrated treatment system for mental disorders based on BCI technology, aiming to enhance this paper understanding of BCI applications in mental health care. The study examines how different BCI technologies can be utilized at various stages of disease progression, from early diagnosis to long-term management. Additionally, it discusses the potential of BCI in improving patient outcomes, quality of life, and social integration, while addressing ethical considerations and future research directions in this rapidly evolving field.

References

[1] PhRMA. 2014 Global advances in drug development for psychiatric disorders. Journal of China Pharmaceutical University, 2014, (3): 324.

[2] He Z., Chen L., Xu J., et al. Unified convolutional sparse transformer for disease diagnosis, monitoring, drug development, and therapeutic effect prediction from EEG raw data. Biology (Basel), 2024, 13(4): 203.

[3] Jaworska N., de la Salle S., Ibrahim M. H., Blier P., Knott V. Leveraging machine learning approaches for predicting antidepressant treatment response using electroencephalography (EEG) and clinical data. Frontiers in Psychiatry, 2019, 9: 768.

[4] McCall J. G., Qazi R., Shin G., et al. Preparation and implementation of optofluidic neural probes for in vivo wireless pharmacology and optogenetics. Nature Protocols, 2017, 12(2): 219-237.

[5] Vidal, J. J. Toward direct brain-computer communication. Annual Review of Biophysics and Bioengineering, 1973, 2(1): 157.

[6] Krauss J. K., Lipsman N., Aziz T., et al. Technology of deep brain stimulation: current status and future directions. Nature Reviews Neurology, 2021, 17(2): 75-87. Dean&Francis Sai Hong

[7] Sridhar C., Bhat S., Acharya U. R., Adeli H., Bairy G. M. Diagnosis of attention deficit hyperactivity disorder using imaging and signal processing techniques. Computers in Biology and Medicine, 2017, 88: 93-99.

[8] Mumtaz W., Qayyum A. A deep learning framework for automatic diagnosis of unipolar depression. International Journal of Medical Informatics, 2019, 132: 103983.

[9] Chen T., Mao S. Advances in the application of in vivo drug analysis technology in clinical pharmacy. Journal of Pharmaceutical Practice and Service, 2024, 42(2): 60-65.

[10] De Pieri M., Rochas V., Sabe M., Michel C., Kaiser S. Pharmaco-EEG of antipsychotic treatment response: a systematic review. Schizophrenia (Heidelberg), 2023, 9(1): 85.

[11] Bagby R. M., Ryder A. G., Schuller D. R., Marshall M. B. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? American Journal of Psychiatry, 2004, 161(12): 2163-2177.

[12] Luo Ruipeng, Zou Renling, Meng Lingpeng, et al. Research on EEG recognition of depression based on machine learning. Intelligent Computers and Applications, 2023, 13(11): 82-87.

[13] Rasheed K., Qayyum A., Qadir J., et al. Machine learning for predicting epileptic seizures using EEG signals: a review. IEEE Reviews in Biomedical Engineering, 2021, 14: 139-155.

[14] Xu J., Zhang C., Tang Y. Research progress on the targets of deep brain stimulation in the treatment of treatment-resistant depression. Chinese Journal of Neuropsychiatric Diseases, 2022, 48(5): 310-314.

[15] Zhou C., Zhang H., Qin Y., et al. A systematic review and meta-analysis of deep brain stimulation in treatment-resistant depression. Progress in Neuropsychopharmacology & Biological Psychiatry, 2018, 82: 224-232.

[16] Slepneva N., Basich-Pease G., Reid L., et al. Therapeutic DBS for OCD suppresses the default mode network. Preprint. bioRxiv, 2024.

[17] Qazi R., Gomez A. M., Castro D. C., et al. Wireless optofluidic brain probes for chronic neuropharmacology and photostimulation. Nature Biomedical Engineering, 2019, 3(8): 655-669.

[18] Saeedi, A., Maghsoudi, A., Rahatabad, F. N. Depression diagnosis and drug response prediction via recurrent neural networks and transformers utilizing EEG signals. Preprint. arXiv, 2023.

[19] Naufel S., Klein E. Brain-computer interface (BCI) researcher perspectives on neural data ownership and privacy. Journal of Neural Engineering, 2020, 17(1): 016039.

Downloads

Published

2024-12-31

Issue

Vol. 2 No. 6 (2024): Volume 2, Issue 6

Section

Articles

License

Copyright (c) 2024 by the authors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.